SCHEMBL6323650

SCHEMBL6323650

CC(CCc1ccccc1)NC(=O)c1c(-c2coc3ccccc23)noc1N

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.47
HPGD P15428 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HTT P42858 2/20 0.46
MEN1 O00255 2/20 0.46
USP2 O75604 1/20 0.44
TSHR P16473 1/20 0.44
ALDH1A1 P00352 2/20 0.43
GAA P10253 1/20 0.43
POLB P06746 3/20 0.43
LMNA P02545 2/20 0.42
HSP90AA1 P07900 1/20 0.42
ATM Q13315 1/20 0.42
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317238 0.89 L3MBTL1 (0.44) KMT2AHPGDSMN1; SMN2ALDH1A1GAA
SCHEMBL885709 0.88 SMN1; SMN2 (0.35) KMT2ASMN1; SMN2POLB
SCHEMBL6316505 0.87 RAB9A (0.42) KMT2AHPGDSMN1; SMN2HTTMEN1
SCHEMBL6315860 0.87 L3MBTL1 (0.38) POLBTAS1R3TAS1R1
SCHEMBL6323271 0.86 ACACB (0.37) KMT2AMEN1POLBTAS1R3TAS1R1
SCHEMBL6316467 0.86 L3MBTL1 (0.38) POLBTAS1R3TAS1R1
SCHEMBL6323089 0.85 NPC1 (0.44) KMT2AHPGDSMN1; SMN2HTTMEN1
SCHEMBL6317875 0.83 L3MBTL1 (0.52) KMT2AHPGDSMN1; SMN2HTTMEN1
SCHEMBL6315149 0.83 RAB9A (0.45) KMT2ASMN1; SMN2HTTMEN1ALDH1A1
SCHEMBL6323394 0.83 L3MBTL1 (0.37) KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 KMT2A 1089/4885HPGD 2923/4885SMN1; SMN2 2766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.